Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.44 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18803141 | 0.89 | ALDH1A1 (0.36) | ALDH1A1MAPTMEN1KMT2ALMNA | |
| SCHEMBL2708359 | 0.83 | ALDH1A1 (0.38) | ALDH1A1MAPTMEN1KMT2ALMNA | |
| SCHEMBL7885090 | 0.82 | LMNA (0.41) | ALDH1A1MAPTLMNASMN1; SMN2POLB | |
| SCHEMBL7946537 | 0.82 | MEN1 (0.36) | ALDH1A1MAPTMEN1KMT2ALMNA | |
| SCHEMBL13242139 | 0.82 | KAT2B (0.40) | ALDH1A1MAPTMEN1KMT2ALMNA | |
| SCHEMBL18396645 | 0.81 | MAPT (0.41) | ALDH1A1MAPTMEN1KMT2ALMNA | |
| SCHEMBL12354220 | 0.81 | LMNA (0.40) | ALDH1A1MAPTMEN1KMT2ALMNA | |
| SCHEMBL30115273 | 0.79 | MAPT (0.42) | ALDH1A1MAPTMEN1KMT2ALMNA | |
| SCHEMBL29129582 | 0.79 | MAPT (0.52) | ALDH1A1MAPTMEN1KMT2ALMNA | |
| SCHEMBL6640614 | 0.77 | ALDH1A1 (0.37) | ALDH1A1MAPTMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117247383-A | Pharmaceutical compounds, salts thereof, formulations thereof, and methods of making and using the same | 基因技术公司 | 2023-12-19 | — | — | CN | claimed |
| CN-112105616-B | Pharmaceutical compounds, salts thereof, formulations thereof, and methods of making and using the same | 基因技术公司 | 2023-09-01 | — | — | CN | claimed |
| CN-112105616-A | Pharmaceutical compounds, salts thereof, formulations thereof, and methods of making and using the same | 基因技术公司 | 2020-12-18 | — | — | CN | claimed |
| EP-3746441-A1 | PHARMACEUTICAL COMPOUND, SALTS THEREOF, FORMULATIONS THEREOF, AND METHODS OF MAKING AND USING SAME | GENENTECH, INC. (US) | 2020-12-09 | — | — | EP | claimed |
| US-20200361933-A1 | PHARMACEUTICAL COMPOUND, SALTS THEREOF, FORMULATIONS THEREOF, AND METHODS OF MAKING AND USING SAME | GENENTECH, INC. | 2020-11-19 | — | — | US | claimed |
| WO-2019152863-A1 | PHARMACEUTICAL COMPOUND, SALTS THEREOF, FORMULATIONS THEREOF, AND METHODS OF MAKING AND USING SAME | GENENTECH, INC. (US) | 2019-08-08 | — | — | WO | claimed |
| US-20240409539-A1 | PHARMACEUTICAL COMPOUND, SALTS THEREOF, FORMULATION THEREOF, AND METHODS OF MAKING AND USING SAME | GENENTECH, INC. | 2024-12-12 | — | — | US | disclosed |
| CN-117247383-A | Pharmaceutical compounds, salts thereof, formulations thereof, and methods of making and using the same | 基因技术公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-112105616-B | Pharmaceutical compounds, salts thereof, formulations thereof, and methods of making and using the same | 基因技术公司 | 2023-09-01 | — | — | CN | disclosed |
| EP-3746441-B1 | PHARMACEUTICAL COMPOUND, SALTS THEREOF, FORMULATIONS THEREOF, AND METHODS OF MAKING AND USING SAME | GENENTECH INC (US) | 2023-04-05 | — | — | EP | disclosed |
| EP-3746441-B1 | PHARMACEUTICAL COMPOUND, SALTS THEREOF, FORMULATIONS THEREOF, AND METHODS OF MAKING AND USING SAME | GENENTECH INC (US) | 2023-04-05 | — | — | EP | disclosed |
| CN-112105616-A | Pharmaceutical compounds, salts thereof, formulations thereof, and methods of making and using the same | 基因技术公司 | 2020-12-18 | — | — | CN | disclosed |
| CN-108368127-B | Compounds and their use as EP4 receptor antagonists | 武田药品工业株式会社 | 2020-12-11 | — | — | CN | disclosed |
| WO-2017014323-A1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-26 | — | — | WO | disclosed |
| US-20150094311-A1 | NOVEL SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS GAMMA SECRETASE MODULATORS | CELLZOME LTD (GB) | 2015-04-02 | — | — | US | disclosed |
| US-20150094311-A1 | NOVEL SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS GAMMA SECRETASE MODULATORS | CELLZOME LTD (GB) | 2015-04-02 | — | — | US | disclosed |
| US-8946426-B2 | Substituted bicyclic heterocyclic compounds as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946426-B2 | Substituted bicyclic heterocyclic compounds as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20110281881-A1 | NOVEL SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2011-11-17 | — | — | US | disclosed |
| US-20110281881-A1 | NOVEL SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361933-A1 | PHARMACEUTICAL COMPOUND, SALTS THEREOF, FORMULATIONS THEREOF, AND METHODS OF MAKING AND USING SAME | SLC10A1, SLC5A6, SLC26A4 | ALDH1A1 825/4885MAPT 862/4885MEN1 122/4885 |
| US-20240409539-A1 | PHARMACEUTICAL COMPOUND, SALTS THEREOF, FORMULATION THEREOF, AND METHODS OF MAKING AND USING SAME | SLC10A1, SLC26A4, AQP1 | ALDH1A1 586/4885MAPT 686/4885MEN1 158/4885 |
| US-20110281881-A1 | NOVEL SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, APH1A | ALDH1A1 1378/4885MAPT 2969/4885MEN1 2658/4885 |
| US-20150094311-A1 | NOVEL SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, APH1A | ALDH1A1 1378/4885MAPT 2969/4885MEN1 2658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.